Coverage

Pharma & biotech

KOLs, former regulators, and clinical investigators who've been inside the therapeutic area you're studying, not adjacent to it.

Expert types

Key opinion leaders (KOLs)Former FDA / EMA reviewersClinical investigatorsCommercial & brand leadsMedical affairs veterans

Common use cases

Pipeline & mechanism diligence

Validate a therapeutic mechanism or competitive pipeline read with practicing specialists in the relevant indication.

Regulatory pathway assessment

Get a former reviewer's perspective on approval strategy, trial design, or likely agency questions.

Launch readiness

Stress-test commercial and access assumptions with brand leads who've run comparable launches.

Competitive positioning

Understand how prescribers actually weigh your asset against the standard of care.

Questions we help answer

  • How will oncologists actually sequence this drug relative to the current standard of care?
  • What would make the FDA push back on this trial design, based on precedent?
  • Is the KOL enthusiasm at conferences translating into real prescribing intent?
  • What did the competitor's Phase 2 readout actually tell prescribers, versus what the press release said?

In practice

An investor needed to know whether oncologists would really switch regimens on a competitor's Phase 2 readout, or whether the market was overreacting to a press release. We sourced three practicing oncologists across academic and community settings within three business days, scoped around prescribing behavior rather than trial mechanics, and came back with a split view by practice setting that looked nothing like the market's first reaction.

Composite example, illustrative only.